Non-alcoholic Steatohepatitis Clinical Trials

Description

Global Non-alcoholic Steatohepatitis Clinical Trials Market to Reach US$4.3 Billion by 2030

The global market for Non-alcoholic Steatohepatitis Clinical Trials estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$828.8 Million While China is Forecast to Grow at 5.3% CAGR

The Non-alcoholic Steatohepatitis Clinical Trials market in the U.S. is estimated at US$828.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$697.8 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market - Key Trends & Drivers Summarized

Why Is the Demand for NASH Clinical Trials Growing Rapidly?

The rising global burden of non-alcoholic steatohepatitis (NASH) has fueled the demand for clinical trials aimed at developing effective therapeutic interventions for this complex liver disease. Unlike other metabolic disorders, NASH currently has no FDA-approved treatments, making clinical research essential for identifying potential drug candidates that can prevent liver fibrosis and disease progression. Pharmaceutical and biotechnology companies are investing heavily in NASH drug development, with multiple compounds in Phase II and III clinical trials targeting different disease pathways, including inflammation, fibrosis, and lipid metabolism. The need for diverse patient populations in trials is also increasing, as researchers seek to understand how genetic, lifestyle, and metabolic factors influence disease progression and treatment response. Additionally, regulatory agencies are providing fast-track designations and priority reviews for promising NASH therapies, encouraging investment in large-scale clinical trials. As the healthcare industry prioritizes metabolic liver disease research, the NASH clinical trials market is experiencing significant expansion, paving the way for the next generation of liver therapeutics.

What Challenges Are Impacting the Progress of NASH Clinical Trials?

Despite increased investment in NASH research, clinical trials face several hurdles that affect drug development timelines and success rates. One of the most significant challenges is patient recruitment and retention, as NASH is often asymptomatic in its early stages, leading to difficulties in identifying eligible trial participants. The reliance on liver biopsy as a primary endpoint for assessing treatment efficacy also poses a challenge, as it limits patient willingness to participate in invasive procedures. Additionally, the heterogeneity of NASH pathophysiology complicates drug development, as different mechanisms contribute to disease progression in various patient subgroups. Regulatory uncertainties and varying approval criteria across global markets further slow down trial progression, requiring companies to navigate complex compliance frameworks. Moreover, the high failure rate of NASH drug candidates in late-stage trials has raised concerns about the commercial viability of potential treatments. Addressing these challenges will require improved trial designs, better non-invasive biomarkers, and greater collaboration between stakeholders to accelerate drug discovery efforts.

How Are Innovations and Emerging Therapies Shaping the Future of NASH Clinical Trials?

Advancements in drug development and clinical trial methodologies are transforming NASH research, increasing the likelihood of successful therapeutic breakthroughs. Precision medicine approaches are enabling patient stratification based on genetic and metabolic profiles, allowing researchers to tailor treatments to specific disease subtypes. The use of AI-powered clinical trial management systems is improving patient recruitment, reducing dropout rates, and optimizing trial efficiency. Non-invasive imaging techniques, such as multiparametric MRI and transient elastography, are being integrated into trials to assess liver health without requiring biopsies, improving patient compliance. Additionally, combination therapies targeting multiple disease pathways simultaneously are showing promise in addressing the complexity of NASH progression. The emergence of novel drug classes, including FXR agonists, PPAR agonists, and anti-fibrotic agents, is further diversifying the therapeutic landscape, increasing the chances of successful treatment approvals. As these innovations continue to evolve, they are reshaping the NASH clinical trials market, accelerating the development of effective and accessible liver disease treatments.

What Is Driving the Growth of the NASH Clinical Trials Market?

The growth in the NASH clinical trials market is driven by several factors, including the urgent need for FDA-approved treatments, increasing prevalence of metabolic liver diseases, and advancements in non-invasive diagnostic tools. The expansion of pharmaceutical investments in metabolic disorder therapeutics is fueling trial activity, with multiple biopharma companies competing to bring the first approved NASH drug to market. The growing adoption of digital health platforms and AI-driven patient monitoring solutions is improving trial efficiency, reducing costs, and enhancing data collection accuracy. Additionally, regulatory incentives such as orphan drug designations, fast-track approvals, and breakthrough therapy designations are encouraging drug developers to invest in high-risk, high-reward NASH research. The increasing role of real-world evidence (RWE) in trial designs is further shaping market dynamics, providing valuable insights into long-term treatment outcomes. As clinical research continues to evolve, the NASH clinical trials market is expected to witness rapid growth, driving progress toward effective and scalable treatments for this widespread liver disease.

SCOPE OF STUDY:

The report analyzes the Non-alcoholic Steatohepatitis Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Study (Interventional Studies, Observational Studies, Expanded Access Studies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

89bio, Inc.
Akero Therapeutics, Inc.
Alimentiv Inc.
Allergan plc
Boehringer Ingelheim
Cadila Healthcare Limited
FOMAT Medical Research
Gilead Sciences, Inc.
ICON plc
Intercept Pharmaceuticals, Inc.
Laboratory Corporation of America Holdings (LabCorp)
Madrigal Pharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Poxel SA
ProSciento, Inc.
Viking Therapeutics, Inc.
Zealand Pharma A/S

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Product Code: MCP32361

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Non-alcoholic Steatohepatitis Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Obesity and Type 2 Diabetes Propels Growth in NASH Clinical Trials
- Increased Awareness and Diagnosis Rates Expands Addressable Market Opportunity for NASH Therapeutics
- Shift Toward Non-Invasive Diagnostic Tools Drives Adoption of Innovative Biomarkers in Clinical Trials
- Regulatory Push for Accelerated Approval Pathways Strengthens Business Case for NASH Drug Development
- Advances in Fibrosis Scoring and Imaging Technologies Accelerate Demand for Precision Trial Design
- Growing Investment from Big Pharma Spurs Growth in Late-Stage Clinical Trials
- Integration of AI and Predictive Analytics in Trial Design Enhances Trial Efficiency and Outcomes
- Surging Demand for Personalized Medicine Approaches Drives Growth in Stratified NASH Trial Models
- Rising Cost and Complexity of Clinical Trials Throws the Spotlight on Outsourcing and CRO Partnerships
- Expanded Use of Real-World Evidence in Trial Protocols Sustains Growth in Adaptive Trial Frameworks
- Increasing Emphasis on Patient-Centric Trials Generates Demand for Digital Health Platforms and Remote Monitoring
- Globalization of Clinical Trials Expands Geographic Footprint and Access to Diverse Patient Populations
- Limited Availability of Approved Therapies Creates Unmet Need, Propelling Innovation in Pipeline Candidates
- Growing Focus on Combination Therapies Drives Complexity and Scope of Trial Designs
- Reimbursement Uncertainty and Market Access Challenges Threaten Commercial Viability Post-Trial
- Rising Ethical and Regulatory Scrutiny Throws the Spotlight on Transparency in Trial Data and Protocols
- Emergence of NASH as a Comorbidity in Cardiometabolic Disorders Strengthens Business Case for Integrated Trial Models
- Advances in Omics Technologies Propel Growth of Biomarker-Driven Clinical Trials
- Competitive Pressure to Shorten Time-to-Market Drives Demand for Decentralized Trial Models
- Strategic Collaborations Between Biotech and Academic Institutions Spur Innovation in Early-Stage Trials
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Non-alcoholic Steatohepatitis Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for Interventional Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for Interventional Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World 6-Year Perspective for Observational Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Expanded Access Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 17: World 6-Year Perspective for Expanded Access Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 18: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 19: USA 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 20: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
CANADA
- TABLE 22: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 23: Canada 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 24: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 25: Canada 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
JAPAN
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 26: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Japan 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 28: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 29: Japan 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
CHINA
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 30: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 31: China 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 32: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: China 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
EUROPE
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 34: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 35: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 36: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 37: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 38: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
FRANCE
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 40: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 41: France 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 42: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 43: France 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
GERMANY
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 44: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Germany 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 46: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 47: Germany 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
ITALY
- TABLE 48: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 49: Italy 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 50: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Italy 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
UNITED KINGDOM
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 52: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 53: UK 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 54: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 55: UK 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
REST OF EUROPE
- TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Rest of Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 59: Rest of Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
ASIA-PACIFIC
- Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 61: Asia-Pacific 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Asia-Pacific 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
REST OF WORLD
- TABLE 64: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 65: Rest of World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
- TABLE 66: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 67: Rest of World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030